Page 2 - கோலின்ஸ் நேரம் ஸ்டாம்பர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கோலின்ஸ் நேரம் ஸ்டாம்பர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கோலின்ஸ் நேரம் ஸ்டாம்பர் Today - Breaking & Trending Today

Investegate |Syncona Limited Announcements | Syncona Limited: Autolus reports Q1 2021 Financial Results


06 May 2021
Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes that its portfolio company, Autolus Therapeutics Plc (NASDAQ: AUTL) (Autolus), announced its operational and financial results for the first quarter ended March 31, 2021.
The announcement can be accessed on Autolus  investor website at 
https://www.autolus.com/investor-relations
 and full text of the announcement from Autolus is contained below. Autolus management will host a conference call today, at 8:30 a.m. EDT/ 1:30pm GMT to discuss the company s financial results and operational update. To listen to the webcast and view the accompanying slide presentation, please go to: ....

City Of , United Kingdom , United States , Susana Noonan , Julia Wilson , Collins Tim Stamper , Martin Murphy , Annabel Clay , Muhammad Al , Ben Atwell Natalie , Exchange Commission On , European Hematology Association , Sa Noonan Communications , International Nonproprietary Name , Translational Sciences , Regulatory Agency , Exchange Commission , Autolus Therapeutics Plc , European Medicines Agency , Syncona Ltd , Syncona Limited , Natalie Garland Collins , Therapeutics Reports First Quarter , Autolus Therapeutics , Christian Itin , Acute Lymphoblastic Leukemia ,

Investegate |Syncona Limited Announcements | Syncona Limited: New commitment to Quell in largest ever Series A


11 February 2021
·
Further commitment of £25.3 million in a £61.0 million expanded Series A; taking Syncona s total commitment to Quell to £59.3 million
·
First company globally targeting liver transplantation with engineered T regulatory cell therapy; set for clinical entry in the first half of 2022
 
·
Research programmes initiated in Type 1 Diabetes ( T1D ) and Amyotrophic Lateral Sclerosis ( ALS )
Syncona Ltd ( Syncona ) announces a £25.3 million new commitment in a £61.0 million expanded Series A financing for Quell Therapeutics ( Quell ). This is the largest amount of funding to date for any stand-alone engineered T regulatory cell (Treg) company and this new commitment takes Syncona s total commitment to this business to £59.3 million. Syncona has invested £35.1 million of its total commitment and values its investment at that amount (equivalent to cost). Syncona will have a ....

City Of , United Kingdom , Iain Mcgill , Collins Tim Stamper , Martin Murphy , Hans Stauss , Marc Martinez Llordella , Giovanna Lombardi , Alberto Sanchez Fueyo , Emma Morris , Annabel Clay , Ben Atwell Natalie , Elmar Jaeckel , University College London , Department Of Gastroenterology , Syncona Investment Management , Hannover Medical School , Institute Of Immunity , Syncona Ltd , Institute Of Liver , University Of Sheffield , Group Leader , Sheffield Institute For Translational Neuroscience Sitra , Amyotrophic Lateral Sclerosis , Quell Therapeutics , Sheffield Institute ,